TNF and neoplasm: Splenic CD8+ T cells in tumor-bearing mice treated with the combination of 5AZADC and ADU-S100 expressed higher levels of IFN-γ and TNF-α relative to the mice treated with ADU-S100 alone (Fig. 7f, g; Supplementary Fig. 6d, e) indicating that combination therapy stimulates a stronger systemic antitumor T cell response.